Esperion Therapeutics (NASDAQ:ESPR) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note issued to investors on Thursday,Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Esperion Therapeutics Stock Down 21.6 %

Shares of ESPR stock opened at $2.00 on Thursday. The company has a 50 day moving average price of $2.39 and a 200-day moving average price of $2.22. Esperion Therapeutics has a 52 week low of $1.58 and a 52 week high of $3.94. The firm has a market capitalization of $394.08 million, a PE ratio of -3.98 and a beta of 1.01.

Institutional Investors Weigh In On Esperion Therapeutics

A number of large investors have recently made changes to their positions in the company. Eaton Financial Holdings Company LLC purchased a new position in shares of Esperion Therapeutics in the third quarter worth approximately $73,000. Barclays PLC raised its holdings in Esperion Therapeutics by 99.6% in the 3rd quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 154,509 shares during the period. Geode Capital Management LLC increased its position in Esperion Therapeutics by 4.1% in the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after buying an additional 171,609 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in Esperion Therapeutics in the third quarter worth about $606,000. Finally, Anson Funds Management LP bought a new position in shares of Esperion Therapeutics in the third quarter worth about $540,000. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.